The patent was announced by Fate Therapeutics Inc., a closely held San Diego
company that has an exclusive license from MIT and Jaenisch, one of the
company’s founders. Shinya Yamanaka , a researcher at Kyoto University in
Japan, “was the first one to do it, we had the idea first,”